Beyond equity: Why venture debt is reshaping European biotech

<p>In this episode of Denatured, you’ll hear from Jennifer McMahon, partner at Seroba and Joey Mason, venture partner at Claret Capital. We dig into how venture debt buys time when equity can’t — and how Europe’s funding gaps, tranching habits and slower urgency shape who uses it well.</p><p><b><strong>Host</strong></b></p><p><a href="https://www.linkedin.com/in/jennifersmithparker/" rel="noopener noreferrer nofollow">Jennifer C. Smith-Parker</a>, Director of Insights, BioSpace</p><p><b><strong>Guests</strong></b></p><p><a href="https://www.linkedin.com/in/jennifer-mcmahon-564b6835/" rel="noopener noreferrer nofollow">Jennifer McMahon</a>, Partner, Seroba</p><p><a href="https://www.linkedin.com/in/joey-mason/" rel="noopener noreferrer nofollow">Joey Mason</a>, Venture Partner, Claret Capital</p><p><i><em>Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.</em></i></p>